1. Home
  2. AVXL vs NMRA Comparison

AVXL vs NMRA Comparison

Compare AVXL & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anavex Life Sciences Corp.

AVXL

Anavex Life Sciences Corp.

HOLD

Current Price

$4.37

Market Cap

397.6M

Sector

Health Care

ML Signal

HOLD

NMRA

Neumora Therapeutics Inc.

HOLD

Current Price

$2.23

Market Cap

424.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVXL
NMRA
Founded
2004
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.6M
424.4M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
AVXL
NMRA
Price
$4.37
$2.23
Analyst Decision
Strong Buy
Buy
Analyst Count
3
8
Target Price
$22.00
$8.00
AVG Volume (30 Days)
4.6M
1.1M
Earning Date
11-25-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.86
$0.61
52 Week High
$14.44
$11.57

Technical Indicators

Market Signals
Indicator
AVXL
NMRA
Relative Strength Index (RSI) 40.02 44.31
Support Level $3.62 $2.13
Resistance Level $4.84 $2.36
Average True Range (ATR) 0.42 0.19
MACD 0.23 -0.04
Stochastic Oscillator 74.53 16.67

Price Performance

Historical Comparison
AVXL
NMRA

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Share on Social Networks: